Jupipac 260 Injection contains Paclitaxel at a concentration of 6 mg/ml and is an antineoplastic agent used primarily in the treatment of various malignancies, including ovarian, breast, and non-small cell lung cancers. Paclitaxel functions by stabilizing microtubules and inhibiting their depolymerization, thereby disrupting the normal process of cell division and inducing apoptosis in rapidly proliferating cancer cells. Jupipac 260 is administered intravenously under strict medical supervision, with dosage and infusion rates tailored according to the specific cancer type, stage, and patient tolerance. Premedication with corticosteroids, antihistamines, and H2 antagonists is recommended to minimize hypersensitivity reactions, which are among the most common adverse effects. Other potential side effects include myelosuppression, peripheral neuropathy, alopecia, and gastrointestinal disturbances. Due to its cytotoxic nature, Jupipac 260 should be handled with caution, ensuring appropriate protective measures to prevent exposure. It is contraindicated in patients with hypersensitivity to paclitaxel or any formulation excipients. Regular monitoring of blood counts, liver function, and cardiac status is essential during therapy. Jupipac 260 Injection is a critical component of combination chemotherapy regimens, contributing significantly to improved clinical outcomes in cancer management.